{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:24:09Z","timestamp":1790958249862,"version":"4.1.0"},"reference-count":30,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: We aimed to evaluate the prognostic value of imaging biomarkers on 18F-FDG PET\/CT in extensive-stage small-cell lung cancer (ES-SCLC) patients undergoing first-line chemo-immunotherapy. Methods: In this multicenter and retrospective study, we considered two cohorts, depending on the type of first-line therapy: chemo-immunotherapy (CIT) versus chemotherapy alone (CT). All patients underwent baseline 18-FDG PET\/CT before therapy between June 2016 and September 2021. We evaluated clinical, biological, and PET parameters, and used cutoffs from previously published studies or predictiveness curves to assess the association with progression-free survival (PFS) or overall survival (OS) with Cox prediction models. Results: Sixty-eight patients were included (CIT: CT) (36: 32 patients). The median PFS was 5.9:6.5 months, while the median OS was 12.1:9.8 months. dNLR (the derived neutrophils\/(leucocytes-neutrophils) ratio) was an independent predictor of short PFS and OS in the two cohorts (p &lt; 0.05). High total metabolic tumor volume (TMTVhigh if &gt; 241 cm3) correlated with outcomes, but only in the CIT cohort (PFS for TMTVhigh in multivariable analysis: HR 2.5; 95%CI 1.1\u20135.9). Conclusion: Baseline 18F-FDG PET\/CT using TMTV could help to predict worse outcomes for ES-SCLC patients undergoing first-line CIT. This suggests that baseline TMTV may be used to identify patients that are unlikely to benefit from CIT.<\/jats:p>","DOI":"10.3390\/cancers15082223","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T03:19:54Z","timestamp":1681096794000},"page":"2223","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Total Metabolic Tumor Volume on 18F-FDG PET\/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy"],"prefix":"10.3390","volume":"15","author":[{"given":"Julia","family":"Grambow-Velilla","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, AP-HP, Avicenne University Hospital, 93000 Bobigny, France"},{"name":"Department of Nuclear Medicine, AP-HP, European Hospital Georges-Pompidou, University of Paris, 75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2584-5478","authenticated-orcid":false,"given":"Romain-David","family":"Seban","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Institut Curie, 92210 Saint-Cloud, France"},{"name":"Laboratoire d\u2019Imagerie Translationnelle en Oncologie, Inserm, Institut Curie, 91401 Orsay, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kader","family":"Chouahnia","sequence":"additional","affiliation":[{"name":"Department of Medical Thoracic and Medical Oncology, AP-HP, Avicenne University Hospital, 93000 Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9749-4937","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Assi\u00e9","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Pneumologie, CHU Henri Mondor, UPEC, 94000 Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Champion","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Institut Curie, 92210 Saint-Cloud, France"},{"name":"Laboratoire d\u2019Imagerie Translationnelle en Oncologie, Inserm, Institut Curie, 91401 Orsay, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[{"name":"Institut du Thorax Curie Montsouris, Institut Curie, 75005 Paris, France"},{"name":"Paris Saclay, UVSQ, UFR Simone Veil, 78180 Versailles, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Bonardel","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Centre Cardiologique du Nord, 93200 Saint-Denis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Matton","sequence":"additional","affiliation":[{"name":"Department of Medical Thoracic and Medical Oncology, AP-HP, Avicenne University Hospital, 93000 Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Soussan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, AP-HP, Avicenne University Hospital, 93000 Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4290-5524","authenticated-orcid":false,"given":"Christos","family":"Choua\u00efd","sequence":"additional","affiliation":[{"name":"Department of Pneumology, Centre Hospitalier Inter-Communal de Cr\u00e9teil, Paris-Est University, 94010 Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0872-2983","authenticated-orcid":false,"given":"Boris","family":"Duchemann","sequence":"additional","affiliation":[{"name":"Department of Medical Thoracic and Medical Oncology, AP-HP, Avicenne University Hospital, 93000 Bobigny, France"},{"name":"Inserm UMR 1272 \u201cHypoxie et Poumon\u201d, UFR SMBH L\u00e9onard de Vinci, Universit\u00e9 Sorbonne Paris Nord, 93000 Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/978-3-319-40389-2_14","article-title":"Small Cell Lung Cancer","volume":"170","author":"Bernhardt","year":"2016","journal-title":"Cancer Treat. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/JTO.0000000000000548","article-title":"Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer","volume":"10","author":"Foster","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus Platinum-Etoposide versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial","volume":"394","author":"Dvorkin","year":"2019","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.21.01881","article-title":"Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options","volume":"40","author":"Zugazagoitia","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","article-title":"Tumour Burden and Efficacy of Immune-Checkpoint Inhibitors","volume":"19","author":"Marabelle","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00259-022-05780-2","article-title":"Joint EANM\/SNMMI\/ANZSNM Practice Guidelines\/Procedure Standards on Recommended Use of [18F]FDG PET\/CT Imaging during Immunomodulatory Treatments in Patients with Solid Tumors Version 1.0","volume":"49","author":"Lopci","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Christensen, T.N., Andersen, P.K., Langer, S.W., and Fischer, B.M.B. (2021). Prognostic Value of 18F-FDG-PET Parameters in Patients with Small Cell Lung Cancer: A Meta-Analysis and Review of Current Literature. Diagnostics, 11.","DOI":"10.3390\/diagnostics11020174"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1097\/RLU.0000000000001886","article-title":"Role of Various Metabolic Parameters Derived from Baseline 18F-FDG PET\/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy","volume":"43","author":"Sharma","year":"2018","journal-title":"Clin. Nucl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2018.11.002","article-title":"Predictive Biomarkers of Response for Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer","volume":"106","author":"Prelaj","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00259-019-04615-x","article-title":"Baseline Metabolic Tumor Burden on FDG PET\/CT Scans Predicts Outcome in Advanced NSCLC Patients Treated with Immune Checkpoint Inhibitors","volume":"47","author":"Seban","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11548-012-0749-7","article-title":"Independent Prognostic Value of Whole-Body Metabolic Tumor Burden from FDG-PET in Non-Small Cell Lung Cancer","volume":"8","author":"Zhang","year":"2013","journal-title":"Int. J. Comput. Assist. Radiol. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0169-5002(00)00105-7","article-title":"Predictive and Prognostic Factors in Small Cell Lung Cancer: Current Status","volume":"28","author":"Yip","year":"2000","journal-title":"Lung Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM Procedure Guidelines for Tumour Imaging: Version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","article-title":"Metabolic Tumour Volumes Measured at Staging in Lymphoma: Methodological Evaluation on Phantom Experiments and Patients","volume":"41","author":"Meignan","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the Lung Immune Prognostic Index with Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13321-015-0100-8","article-title":"Predictiveness Curves in Virtual Screening","volume":"7","author":"Guillemain","year":"2015","journal-title":"J. Cheminform."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/bimj.201000153","article-title":"Discrimination Measures for Survival Outcomes: Connection between the AUC and the Predictiveness Curve","volume":"53","author":"Viallon","year":"2011","journal-title":"Biom. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.annonc.2022.02.180","article-title":"149P Total Metabolic Tumor Volume: A New Potential Prognostic Factor in SCLC","volume":"33","author":"Andrini","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2021.03.020","article-title":"Baseline Total Metabolic Tumour Volume on 2-Deoxy-2-[18F]Fluoro-d-Glucose Positron Emission Tomography-Computed Tomography as a Promising Biomarker in Patients with Advanced Non\u2013Small Cell Lung Cancer Treated with First-Line Pembrolizumab","volume":"150","author":"Conci","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver Metastasis Restrains Immunotherapy Efficacy via Macrophage-Mediated T Cell Elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.dld.2022.01.122","article-title":"Optimizing Systemic Therapy for Advanced Hepatocellular Carcinoma: The Key Role of Liver Function","volume":"54","author":"Cabibbo","year":"2022","journal-title":"Dig. Liver Dis."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Seban, R.-D., Assi\u00e9, J.-B., Giroux-Leprieur, E., Massiani, M.-A., Soussan, M., Bonardel, G., Chouaid, C., Playe, M., Goldfarb, L., and Duchemann, B. (2020). Association of the Metabolic Score Using Baseline FDG-PET\/CT and DNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab. Cancers, 12.","DOI":"10.3390\/cancers12082234"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00432-020-03150-9","article-title":"The Immune-Metabolic-Prognostic Index and Clinical Outcomes in Patients with Non-Small Cell Lung Carcinoma under Checkpoint Inhibitors","volume":"146","author":"Castello","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","article-title":"The Systemic Inflammation-Based Glasgow Prognostic Score: A Decade of Experience in Patients with Cancer","volume":"39","author":"McMillan","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2016.05.031","article-title":"Rapid and Objective CT Scan Prognostic Scoring Identifies Metastatic Patients with Long-Term Clinical Benefit on Anti-PD-1\/-L1 Therapy","volume":"65","author":"Dercle","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2967\/jnumed.119.237768","article-title":"Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of 18F-FDG PET\/CT","volume":"61","author":"Castello","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ebiom.2017.03.029","article-title":"Neutrophil to Lymphocyte Ratio Is Associated with Outcome During Ipilimumab Treatment","volume":"18","author":"Cassidy","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jtho.2019.04.006","article-title":"Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated with Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials","volume":"14","author":"Sorich","year":"2019","journal-title":"J. Thorac. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/8\/2223\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:12:59Z","timestamp":1760123579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/8\/2223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,10]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["cancers15082223"],"URL":"https:\/\/doi.org\/10.3390\/cancers15082223","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,10]]}}}